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ABSTRACT
Decisions about which health-care interventions represent
adequate value to collectively funded health-care systems
are as widespread as they are unavoidable. In the case of
new pharmaceuticals, many countries now require formal
cost-effectiveness analysis to inform this decision-making
process. This requires evidence on parameters associated
with health-related utilities, treatment effects, resource
use, and costs, for which data from available regulatory
trials are invariably absent or highly uncertain. This
uncertainty results from a number of factors including the
predominance of intermediate end points in the clinical
evidence-base and the limited period of follow-up of
patients in clinical studies. Despite these imperfections in
the evidence base, decisions about whether new pharma-
ceuticals are sufﬁciently cost-effective for reimbursement
cannot be side-stepped. Data limitations do, however,
require the use of rigorous analytical methods to support
decision making. Probabilistic decision models and value
of information analysis offer a means of structuring deci-
sion problems, synthesizing all available data, character-
izing the uncertainty in the decision, quantifying the cost
of uncertainty, and establishing the expected value of per-
fect information. This analytical framework is important
because it addresses two fundamental questions about
new pharmaceuticals. First, is the product expected to be
cost-effective on the basis of existing evidence? Second, is
additional research concerning the product itself cost-
effective? In addressing these questions, the analytical
framework can establish when sufﬁcient evidence exists
to sustain a claim for a new pharmaceutical to be cost-
effective.
Keywords: decision theory, reimbursement, uncertainty,
value of information analysis.
Introduction
It is now widely recognized among decision-makers
that value for money represents a key criterion in
deciding which health-care interventions should be
made available in collectively funded health-care
systems. This applies as much to national systems,
such as those in western Europe, as to the more
fragmented arrangements in the United States. A
clear manifestation of this trend relates to the policy
which now exists in many jurisdictions to establish
which new pharmaceutical products represent suf-
ﬁcient value for money to justify reimbursement
from those systems’ limited budgets. A growing
number of jurisdictions formally use cost-effective-
ness evidence as part of their reimbursement deci-
sion making [1]. Many more systems consider
economic evidence in making decisions and have
described their preferred forms of analysis, includ-
ing managed care organizations in the United
States. [2].
The use of economic analysis to support decision
making poses some very fundamental questions
about the most appropriate methods with which to
assess the claims of cost-effectiveness for a new
pharmaceutical. One of these issues relates to how
decisions should be taken under conditions of
uncertainty regarding the evidence-base for a par-
ticular product. A cost-effectiveness analysis needs
to incorporate evidence on numerous parameters
relating to treatment effects, health-related prefer-
ences (utilities), resource use, and costs. Neverthe-
less, ideal data will never exist for all of these
parameters. As a result of the way evidence accu-
mulates for pharmaceuticals, major gaps will inev-
itably exist in a product’s evidence-base. This is
because the primary objective of the research and
development undertaken by pharmaceutical manu-
facturers is to run trials to generate appropriate efﬁ-
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cacy and safety data to obtain a product license.
Nevertheless, most reimbursement authorities will
require evidence relating to the cost-effectiveness of
the product before its widespread use in routine
practice.
The evidence gaps which result from this process
include limited, or highly imprecise, estimates of
nonclinical parameters such as resource use and
health utilities; Phase 3 trials being undertaken in a
range of countries, raising questions regarding how
transferable the data are to particular jurisdictions;
and treatment effect estimates not relating to com-
parisons with all relevant existing treatments. Argu-
ably the most widespread data limitations relate to
the focus of Phase 3 trials on intermediate estimates
of effect rather than ultimate measures of health
gain, and the short duration of observation of treat-
ment effect and outcomes that such trials typically
afford.
In the face of such uncertainties in the evidence-
base, one option is for decisions about reimburse-
ment to be delayed until the data gaps are ﬁlled. Of
course, this amounts to a de facto decision—
namely, that the new product is not as cost-effective
as one or more existing treatments, and should not
be reimbursed. There are several arguments against
this refusal to consider the cost-effectiveness of new
products until “ideal” evidence is available. The
ﬁrst is that such evidence will be difﬁcult to generate
unless some form of reimbursement is agreed, even
if limited to the context of research. This could be
addressed by permitting some form of conditional
reimbursement for a limited period until the data
are generated. Nevertheless, is order for this to be
successful, a second problem would have to be
addressed. Namely, the nature and extent of the
additional evidence that is needed will depend on
how limitations in the evidence base translate into
uncertainty in the cost-effectiveness of a treat-
ment—for example, the imprecision of a resource
use estimate may or may not lead to uncertainty
over the appropriate reimbursement decision. A
third, and related, problem is that the process of
generating additional evidence draws on a pool of
limited resources, and it may be inefﬁcient to
require that they are used for research that would
not be expected to lead to a change in decision com-
pared with one based on existing data. Finally, the
concept of an “ideal” evidence base is itself a chi-
mera: whatever the value of resource devoted to
research, it will never remove all uncertainty in the
reimbursement decision.
If decisions about the cost-effectiveness of new
products are inevitably taken under conditions of
uncertainty, there needs to be a clear analytical
framework within which to address two related
questions. First, does existing imperfect evidence
suggest that an intervention is, in terms of mean
costs  and  effects,  cost-effective?  Second,  given
the uncertainty associated with answering the ﬁrst
question, is additional research, to allow the deci-
sion to be revisited in the future, itself efﬁcient? This
article argues that this analytical framework should
be based around probabilistic decision modeling
and value of information analysis. The second sec-
tion of the article considers what features an ana-
lytical framework should have to address the ﬁrst
question above—the adoption decision based on
current evidence. Using a case study from the tech-
nology appraisal program of the National Institute
for Health and Clinical Excellence (NICE) in the
UK, the third section describes the elements of the
analytical framework necessary to address the sec-
ond question—the cost-effectiveness of additional
research. The article then considers in more detail
the types of uncertainty that need to be adequately
handled using these methods. The next section iden-
tiﬁes some of the policy implications of using this
framework, and offers some conclusions.
Analytical Framework for the Adoption 
Decision
Given that the evidence base associated with new
pharmaceuticals will always have weakness and
limitations, the adoption decision requires an ana-
lytical framework which is explicit in its handling
of uncertainty [3]. This framework will inevitably
have to pull data together from a range of sources
as no single study is likely to provide estimates of
all  relevant  parameters.  Decision  models  provide
a structure for evidence synthesis within which
numerous sources of evidence can be brought
together to estimate the differential costs (the value
of resources consumed) and effects (deﬁned by the
system’s objectives, e.g., health gain) of the options
under comparison. Probabilistic modeling allows
the uncertainty in individual parameters, estimated
from available evidence, to be fully characterized as
random variables which are propagated through the
model using second order Monte Carlo simulation
[4]. Expected cost-effectiveness can be taken from
this distribution. That is, a measure of cost-effec-
tiveness, such as an incremental cost-effectiveness
ratio (ICER), based on mean differential costs and
beneﬁts between the options under comparison. It
should be emphasized that expected cost-effective-
ness is not derived by calculating a distribution of
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ICERs based on the Monte Carlo simulation [5].
Although estimated with uncertainty, mean cost-
effectiveness  represents  the  best  estimate  of
cost-effectiveness.
Given a decision-maker’s objective of maximiz-
ing health gain from available resources, the deci-
sion about reimbursement based on existing
evidence should then be based on how the expected
ICER compares with the decision maker’s threshold
willingness to pay for additional health beneﬁts
which, in resource constrained systems, should
reﬂect the costs and beneﬁts of interventions which
are displaced by the new treatment (i.e., the shadow
price of the budget constraint).
This analytical framework also needs to incorpo-
rate some other key features. The ﬁrst is the need
to compare the new intervention to the full range
of alternative treatments which currently constitute
routine clinical practice. This may include nonphar-
maceutical interventions, watchful waiting and pal-
liative/supportive care. This contrasts with the
practice of simply adopting the comparator which
was used in the regulatory trials which is unlikely to
represent the full picture of current practice in the
jurisdiction of interest. The second feature is the
need to take a consistent perspective on costs. There
are strong arguments in favor of a societal cost per-
spective for cost-effectiveness analysis [6], although
many reimbursement authorities focus on a health
system perspective given that they have no respon-
sibility for altering the total “pot” of resources
available for health care [1].
A third important characteristic of the analytical
framework used to inform the adoption decision is
that there needs to be a clear view of the system’s
maximand—that is, the measure which the system
is trying to maximize from available resources.
Although there is on-going debate in the theoretical
literature about the most appropriate objective for
health-care systems [7], the maximization of health
gain has been explicitly adopted by some systems to
guide their decisions, including NICE in the UK [8].
The way applied economic evaluation has devel-
oped, with its focus on cost-effectiveness analysis, is
consistent with health gain being the maximand. A
fourth, and related issue, is how health gain should
be measured and valued within the analytical
framework. A key criterion is the need for reim-
bursement decisions to use measures which are con-
sistent over time. Given that decisions are taken
across a range of disease areas, the measure should
be generic. For use in cost-effectiveness analysis, all
relevant dimensions of health-related quality of life
(HRQL) and mortality should be expressed on a
single scale which will require the use of multiat-
tribute valuation methods. The quality-adjusted
life-year (QALY) is the most frequently used meas-
ure of health gain used in cost-effectiveness analysis.
Although it satisﬁes the generic and single index
criteria, the need for consistency across decisions
would also require the use of a single approach to
describing health states which is sufﬁciently sensi-
tive to the characteristics of a disease and interven-
tion, and a choice of whose preferences are to be
used to value health states. Although most methods
guidelines from reimbursement agencies support the
use of QALYs, at least as one measure of outcome,
with the exception of NICE [9] few have been pre-
scriptive about the descriptive system, the framed
perspective, and the source of preferences [1].
Analytical Framework for Decisions about 
Further Research
Bayesian Decision Theory
The expected cost-effectiveness of an intervention
indicates whether reimbursement is warranted
given existing evidence. It does not, however, show
whether sufﬁcient evidence exists. In other words,
whether or not a reimbursement agency agrees to
reimburse an intervention, it may ask for additional
research in order for the adoption decision to be re-
examined in the future. Although the uncertainty in
cost-effectiveness should play no direct role in the
adoption decision, it is an essential part of estab-
lishing whether additional research is required.
Therefore, basing the adoption decision on
expected cost-effectiveness does not mean these
decisions can simply be based on little or poor qual-
ity evidence, as long as the decision to conduct fur-
ther research to support adoption, or rejection, is
made simultaneously [10].
For a regulatory agency to establish whether
there is sufﬁcient evidence to support the reimburse-
ment of a particular pharmaceutical, a measure of
the societal value of particular research is required.
An appropriate methodological framework for this
would consider the uncertainty surrounding reim-
bursement in terms of the likelihood of making a
“wrong” decision if the technology is adopted
based on current evidence. It would also view the
value of research as the extent to which further
information will reduce this decision uncertainty.
The value of the additional information generated
by research would be expressed in a way which is
consistent with the objectives and the resource con-
straints of health-care provision. Bayesian decision
theory and value of information analysis provides
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such an analytic framework. These methods have
ﬁrm foundation in statistical decision theory
[11,12], and have been successfully used in other
areas of research such as engineering and environ-
mental risk analysis [13–15]. More recently, these
methods have been extended to setting priorities in
the evaluation of health-care technologies [16,17].
The methods have been applied to different health
technologies [18,19] including a series of case stud-
ies taken from guidance issued by NICE [20]. They
have also been assessed as an input to publicly
funded research priority-setting [21].
An Illustrative Example
Background. The framework outlined above is
illustrated using a stylized example which is based
on the NICE appraisal of orlistat in the treatment
of obesity undertaken in 2001 [22]. The guidance
imposed restrictions and conditions on continued
use in terms of minimum body mass index and
weight loss using dietary control. In addition, it
required that the patients should only continue with
therapy beyond 3 months if they lose at least 5% of
body weight, and only continue beyond 6 months if
they lose at least 10% of body weight. The guidance
suggests that patients are not expected to be on
therapy beyond 12 months.
The appraisal of orlistat and its guidance was
based on the independent assessment report [23]
which identiﬁed 14 randomized controlled trials
(RCTs) and two economic models. None of the
RCTs measured changes in HRQL or utilities,
resource use, regain in weight after cessation of
treatment or any longer-term consequences for mor-
tality of morbidity. Clearly, RCT evidence alone was
not sufﬁcient to establish the cost-effectiveness of
this technology, and there were a number of extrap-
olations and generalizations which needed to be
made. These included establishing how many
patients continue with treatment, which effects both
outcomes to patients and resource use, how changes
in body weight translate into changes in HRQL and
some assessment of the long-term impact on weight,
HRQL and mortality and morbidity after 12 months
of treatment.
Decision model. The structure of this decision
problem can be represented as a simple decision tree
(Fig. 1). The structure compares orlistat with dietary
management and reﬂects the nature of the NICE
guidance outlined above. It involves two chance
nodes: the probability of greater than 5% weight
loss at 3 months and, if this is achieved, the proba-
bility of greater than 10% weight loss at 6 months.
The key end points are weight loss compared with
dietary control, changes in HRQL given weight loss
and the additional cost of 3, 6, and 12 months of
treatment. In this simple case study, long-term mor-
tality and morbidity, and the possibility of sustained
weight loss, have not been modeled. This is in order,
ﬁrst, to simplify the example and, second, because
no evidence seems to exist to support these effects
which were not considered credible by NICE. The
RCT evidence is a crucial source for parameter esti-
mates for the model, particularly the magnitude of
treatment effects (weight loss and probability of
weight loss at 3 and 6 months). Other sources of
data, however, have been taken from nontrial
sources detailed in the assessment report [23]. This
applies, for example, to changes in HRQL and the
resource implications of weight loss.
All decisions about the cost-effectiveness of inter-
ventions are based on uncertain information. The
extent of the evidence available, for each of the
inputs, can be reﬂected in probability distributions
assigned to these estimates, where less information
Figure 1 Structure of the orlistat model
used in the case study.
Orlistat
Dietary control
P(>5% loss at 3 months)
P(<5% loss at 3 months)
P(>10% loss at 6 months given 
>5% loss at 3 months) Weight loss, QALY gain, costs (12 months)
Weight loss, QALY gain, costs (6 months)
Weight loss, QALY gain, costs (3 months)
P(>10% loss at 6 months given 
>5% loss at 3 months)
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and more uncertainty about an input will be
reﬂected in greater variance from the distribution
assigned. The quality and exchangeability or rele-
vance of the evidence available may also be repre-
sented by linking the uncertain estimate to model
inputs through additional uncertain parameters
which can represent potential bias or exchangeabil-
ity. These may be based on evidence of the potential
bias of alternative designs or on expert judgment.
Without access to patient-level data, these distribu-
tions are assigned based on secondary sources (e.g.,
published literature reviewed in the assessment
report [23]) and some judgment about which type
of distribution would be appropriate [24]. The
parameter estimates, their distributions and data
sources are described in Table 1. In general, the
quality of this evidence is very low, and the shape of
the distributions assigned to these parameters
attempts to represent the substantial uncertainty
surrounding these estimates. For an overview of the
process of selecting and ﬁtting probability distribu-
tions in decision models, see Briggs et al. (2002) [4].
Results of the case study—the adoption decision.
The model indicates that orlistat is more effective
but more costly than dietary control alone, with an
incremental cost per additional QALY of £21,400.
Hence if the decision-maker’s threshold willing to
pay is more than £21,400 per QALY, orlistat should
be adopted given existing evidence. Nevertheless,
there is uncertainty in cost-effectiveness, and this is
shown in the cost-effectiveness acceptability curve
(CEAC) in Figure 2. Detailed descriptions of the
derivation and interpretation of CEACs are availa-
ble elsewhere [25–28] In brief, it shows the propor-
tion of the simulations in which (i.e., the probability
that) orlistat is considered cost-effective for a given
maximum willingness to pay on the part of the deci-
sion maker. That is, the proportion of simulations in
which the orlistat has an ICER which is less then the
maximum willingness to pay. One minus this prob-
ability reﬂects the decision uncertainty around
adoption. That is, the probability that, in adopting
orlistat on current evidence, a “wrong” decision
would have been made. The ﬁgure shows that,
Table 1 Data inputs for the orlistat case study
Input parameter
Distribution used to characterize
parameter uncertainty Source
Probability of 5% weight 
loss at 3 months
Beta (286, 214) Meta-analysis of trials with 
3-month follow-up (n = 500) [23]
Probability of 10% weight 
loss at 6 months
Beta (170, 230) Meta-analysis of trials with 
6-month follow-up (n = 500) [23]
Weight loss at 12 months Normal (95% CI 2.19–3.69) Meta-analysis of trials with 
12-month follow-up (n = 548) [23]
Health value (utility) gain per
10 kg weight loss
Log-normal (95% CI 0.0767–0.26) [23]
Total costs per annum Log-normal (95% CI £554–£887) [23]
CI, conﬁdence interval.
Figure 2 Cost-effectiveness acceptability
curve for orlistat in the case study.
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unless the cost-effectiveness threshold is very high,
there will be substantial decision uncertainty sur-
rounding this decision to adopt. For example, at a
threshold willingness to pay of £30,000, the prob-
ability that orlistat is cost-effective is 0.758, giving
an error probability of 0.242. Although this prob-
ability is strictly Bayesian, it is possible to interpret
this in terms of a conventional (“frequentist”) P
value on a one-tailed test on a null hypothesis of no
difference in expected cost-effectiveness [26]. As
such, this probability is much greater than the tra-
ditional rules of inference and statistical signiﬁcance
of 0.05 or 0.1.
Results of the case study—the decision about
further research. How can this error probability be
interpreted? If the wrong decision about adoption is
made, there will be costs in terms of health beneﬁts
and resources forgone. Therefore, the expected cost
of uncertainty is determined jointly by the proba-
bility that a decision based on existing information
will be wrong and the consequences of a wrong
decision. The expected costs of uncertainty can be
interpreted as the expected value of perfect infor-
mation (EVPI) because perfect information can
eliminate the possibility of making the wrong deci-
sion. This is also the maximum that the health-care
system should be willing to pay for additional evi-
dence to inform this decision in the future, and it
places an upper bound on the value of conducting
further research [10,16].
More formally, EVPI is simply the difference
between the payoff with perfect and current infor-
mation. The payoff can be seen in terms of expected
net beneﬁt—for example, expected net monetary
beneﬁt which, for a given option, is: (expected
QALYs ¥ l) - expected costs, where l is the deci-
sion maker’s threshold willingness to pay [5]. More
speciﬁcally, if there are two alternative interventions
(j = 1, 2), with unknown parameters q then, given
the existing evidence, the optimal decision is the
intervention that generates the maximum expected
net beneﬁt [maxj Eq NB(j, q)]. This is the maximum
net beneﬁts over all the iterations from the Monte
Carlo simulation, because each iteration represents
a possible future realization of the existing uncer-
tainty (a possible value of q). With perfect informa-
tion, we would know how the uncertainties would
resolve, which value q will take, before making a
decision and could select the intervention that max-
imizes the net beneﬁt given a particular value of q
[maxj NB(j, q)]. Nevertheless, the true values of q
are unknown; we don’t know which value q will
take. Therefore, the expected value of a decision
taken with perfect information is found by averag-
ing these maximum net beneﬁts over the distribu-
tion of q [Eq maxj NB(j, q)]. The EVPI for an
individual patient is simply the difference between
the expected value of the decision made with perfect
information about the uncertain parameters q, and
the decision made on the basis of existing evidence:
EVPI = Eq maxj NB(j, q) - maxj Eq B(j, q) (1)
This provides the EVPI surrounding the decision
problem for each time this decision is made and for
an individual patient or individual episode. Never-
theless, once information is generated to inform the
decision for an individual patient or a patient epi-
sode, then it is also available to inform the manage-
ment of all other current and future patients. If this
“population” EVPI exceeds the expected costs of
additional research, then it is potentially cost-
effective to conduct further research, current evi-
dence is not sufﬁcient and additional research
should be undertaken.
Figure 3 illustrates the population EVPI for the
orlistat guidance. At a cost-effectiveness threshold
of £30,000, the population EVPI is just more than
£1.5 m. This may well exceed the costs of further
investigation and suggests that further research is
needed to support the adoption of orlistat. When
the threshold for cost-effectiveness—maximum
value of health outcome—is low (much less than
£21,400), the technology is not expected to be cost-
effective and additional information is unlikely to
change that decision (the EVPI is low). Similarly,
when the threshold willingness to pay is higher (i.e.,
much higher than £21,400), the ICER is much
lower than the threshold, oralist would be consid-
ered cost-effective in terms of expected costs and
QALYs and this decision is unlikely to be changed
by further research. In this case the population EVPI
reaches a maximum when the threshold is equal to
the expected ICER; that is, where there is most
uncertainty about whether to adopt or to reject orl-
istat based on existing evidence. Nevertheless, EVPI
does not always reach a maximum at this point.
This is because, although the probability of error
falls as the threshold increases, the value of chang-
ing the decision (the cost of error) also increases, so
the maximum point is determined by the balance of
these two factors.
The value of reducing the uncertainty surround-
ing individual input parameters in the decision
model can also be established. This type of analysis
can be used to focus further research by identifying
those inputs for which more precise estimates
would be most valuable. In some circumstances,
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this will indicate which end points should be
included in further experimental research; in others,
it may focus research on inputs which may not nec-
essarily require experimental design and can be pro-
vided relatively quickly.
This analysis of the value of information associ-
ated with each of the model inputs (parameter
EVPI) is, in principle, conducted in a very similar
way to the EVPI for the decision as a whole [29,30].
The EVPI for a parameter or group of parameters
(j) is again simply the difference between the
expected net beneﬁt with perfect information about
the parameter(s) j and the expected value with cur-
rent information. The expected value with current
information is the same as before [maxj Eq NB(j, q)].
With perfect information, the decision maker would
know how the uncertainties about j would resolve
(which value j will take) before making a decision
and could select the intervention that maximizes
expected net beneﬁt, which must now be calculated
over all the other remaining uncertain parameters
(y) the model [maxj Ey|j NB(j, j, y)]. As before, the
true value of j is unknown so these maximum
expected net beneﬁts must be averaged over the dis-
tribution of j [Ej maxj Ey|j NB(j, j, y)]. The EVPI
for j is the difference between the expected net
beneﬁt with perfect information about j and the
expected value with current information:
EVPI for j = Ej maxj Ey|j NB(j, j, y) - 
maxj Eq NB(j, q) (2)
This does require substantial additional computa-
tion for models where the relationship between the
model’s inputs and expected cost and outcomes is
not linear, for example, in Markov models [19,30].
It should also be noted that, in general, the EVPIs
for individual model inputs will not sum to the
EVPI for the decision problem. This is because both
decision and parameter EVPI depend entirely on
whether additional research would be predicted to
change the decision about the preferred option. In
the simulation process undertaken to estimate this,
if a value of a speciﬁc parameter is drawn some dis-
tance from its mean, it may be insufﬁcient in itself to
change the decision. Nevertheless, when that value
is drawn together with similar extreme values for
other parameters, this combination may well be
enough to change the decision. So there is no simple
relationship between individual parameter and deci-
sion EVPI.
Figure 4 illustrates the EVPIs for individual
parameters associated with the overall population
EVPI at a cost-effectiveness threshold of £21,400.
In this example, it is the EVPI associated with the
changes in HRQL, due to modiﬁcation in body
weight, which is highest. This should not be surpris-
ing as there was limited evidence to link changes in
weight to HRQL, but it is this relationship which is
crucial to establishing the cost-effectiveness of orli-
stat. The EVPIs associated with resource use param-
eters are also relatively high for the same reasons.
Although the EVPI analysis in Figure 3 suggests that
further research may be required to support the
adoption of orlistat, the analysis of the EVPIs for
individual parameters indicates that this may not
need to have an experimental design. This is
because more precise estimates of HRQL changes
and elements of resource use can be established
without an additional clinical trial and could be
based on an observational survey.
Figure 3 The population EVPI for orli-
stat in the case study.
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There remains, however, substantial value of
information associated with the expected loss in
body weight at 12 months, and more precise esti-
mates of this input would require experimental
design. Its also interesting to note that the proba-
bility of remaining on treatment is not associated
with the highest values of information. This is
partly because substantial evidence from the previ-
ous trials exists already. The other reason is that,
when patients come off treatment, the potential
gains in HRQL are lost, but these are offset by
reduction in the intervention costs. It should be
noted that the relative value of information associ-
ated with model inputs will also change with the
cost-effectiveness threshold. Speciﬁcally, those in-
puts which are more closely related to differences in
expected costs will be relatively more important at
low threshold values, and those more closely related
to differences in outcomes will be more important
at high values.
The case study highlights the fact that economic
considerations are central, not only to establishing
how much evidence is required to support the adop-
tion of a technology, but also what type of evidence
will be required and the appropriate research design.
Given an objective to maximize health gain from lim-
ited resources, this framework demonstrates that,
for a particular technology, the amount and type of
evidence required depends on decision uncertainty
and economic decision rules, rather than on rules of
statistical signiﬁcance applied to the trial end point.
It is also clear that different amounts and types of
evidence will be required for different types of tech-
nology relevant to different patient populations.
Types of Uncertainty in Cost-Effectiveness 
Decision Models
Reﬂecting Precision and Quality of Evidence in 
Uncertainty
The orlistat case study highlights the importance of
identifying, quantifying, and incorporating param-
eter uncertainty in decision models. In addition to
the precision of the data, the quality of the evidence
available on a particular part of the model may be
limited. In the case-study, this was seen in the link
between weight loss and HRQL. In some situations,
there will be a complete absence of formal evidence,
and informed judgments may be required. In such
situations, the weakness of the evidence can be
reﬂected in a model through additional uncertainty;
that is, by adding variance to the distribution
around the parameter of interest.
Parallel concerns about precision and quality in
evidence will be part of all reimbursement decisions.
In the context of the NICE appraisal program, for
example, there is a need to compare a number of
new interventions with each other and with several
existing treatments, but there is inevitably an
absence of head-to-head RCTs to compare all
options. The recent appraisal of new interventions
for epilepsy in adults was an example with this
characteristic [31]. In such situations, the use of
indirect methods to estimate treatment effects is
necessary. These can involve relative treatment
effects being estimated for each intervention
through the use of a common comparator [32].
More general statistical models to combine mixed
comparison evidence to provide a consistent set of
Figure 4 EVPI for individual parameters
in the orlistat model in the case study.
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treatment effect estimates have been developed [33–
35]. Again, any additional uncertainty associated
with the use of indirect evidence would be factored
into a model through additional variance in the
parameter distributions.
Modeling Beyond Trial Evidence
Arguably the biggest challenge that reimbursement
agencies have to face in terms of the uncertainty sur-
rounding existing evidence relates to costs and out-
comes which have not been observed directly in
trials. There are two frequent manifestations of this:
linking intermediate outcomes to ultimate measures
of health gain, and extrapolating costs and beneﬁts
over a longer-term time horizon.
Linking changes in intermediate measures to health
gain. The measure of treatment effect which is likely
to be the main driver of the cost-effectiveness of an
intervention will ideally be taken from one or more
RCTs. Nevertheless, such studies are often designed
to show differences in end points other than meas-
ures of health gain such as survival or HRQL.
Indeed, the use of intermediate end points is com-
mon with most chronic diseases, where these end
points are either surrogate markers for outcomes or
intermediate measures of severity. Examples of the
former include blood cholesterol for cholesterol-
lowering drugs and CD4 count or viral load in HIV
treatments. An example of the latter is the Kurtzke
Expanded Disability Status Scale in multiple sclero-
sis. The reasons for the trial focus on these interme-
diate end points are clear: trials designed to show
differences in ultimate health gain would have to be
very large and/or continued for many years, and
licensing authorities have been satisﬁed with inter-
mediate end points for many products. Neverthe-
less, as described above, there is a need for
reimbursement authorities to understand the impact
of interventions in terms of generic measures of
health such as QALYs. The need to develop a link
between intermediate end points and health gain
represents an important role for decision models.
The use of intermediate end points in clinical tri-
als is usually acceptable to licensing authorities
because evidence exists that some degree of corre-
lation exists between the intermediate measure and
ultimate health. In the context of cholesterol-lower-
ing drugs, for example, a number of epidemiologi-
cal studies have shown that serum and low-density
lipoprotein (LDL) are risk factors for coronary
heart disease (CHD) [36,37]. To establish the cost-
effectiveness of cholesterol-lowering therapies in
terms of changes in (quality-adjusted) survival dura-
tion, most published studies have had to rely on risk
equations to make the link between changes in
blood cholesterol and health events [38].
A small number of RCTs of cholesterol-lowering
drugs have been undertaken which provide direct
evidence on the implications for therapies for health
outcomes  [39–41].  These  studies  have  provided
a platform for cost-effectiveness analysis using
patient-level trial data [42,43], but still require
modeling to extrapolate over time. They have also
generated more evidence on the general relationship
between changes in the intermediate end point of
blood cholesterol and health effects. For example,
analyzing the data from the 4S trial using a Cox
proportional hazards model, Pedersen et al. esti-
mated that each additional 1% reduction in LDL
would generate a 1.7% reduction in the risk of
major coronary events [44].
Extrapolating  future  costs  and  beneﬁts. Another
feature of many trials is their short-term follow-up.
This is particularly true of Phase III regulatory trials
where there is a strong need to satisfy the licensing
authorities and hence to get the product to market
as swiftly as possible. For those interventions
between which costs and beneﬁts are likely to differ
over an extensive time period, there will inevitably
be a mismatch between trial follow-up and the
appropriate time horizon of the cost-effectiveness
analysis. This will require the decision model to esti-
mate the costs and health outcomes beyond the
trial, together with the uncertainty associated with
the extrapolation. An example of the need for
extrapolation is for interventions which aim to
reduce mortality. To estimate differences in
expected survival duration (i.e., life-years gained),
the area between the full survival curves needs to be
calculated. Unless the trial has followed-up patients
until all have died—which is only likely in diseases
with poor prognoses like advanced cancer—extrap-
olating survival curves beyond the trial will be nec-
essary. This was the case, for example, with the
NICE appraisal of implantable cardioverter deﬁbril-
lators for arrhythmias, where trial evidence existed
on mortality over a 3- to 4-year follow-up period,
and assumptions about future mortality were
needed as a basis for extrapolation [45].
A key issue with extrapolation relates to the
duration of the treatment effect—that is, the extent
to which the additional effectiveness of an interven-
tion, relative to its comparator(s), is maintained
after the period of observation in the trial. The need
to estimate this future effect is important both when
treatment has been discontinued before the end of
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trial follow-up, and when patients are still under-
going treatment at that point. In an early cost-
effectiveness analysis of zidovudine in HIV,
Schulman et al. estimated the cost-effectiveness of
therapy based on extrapolation beyond the trial
period under a number of assumptions about the
post-trial survival curves [46]. The most “optimis-
tic” assumption, with respect to the beneﬁts of the
therapy, was that the survival curves continued to
diverge after the trial indicating a continuing addi-
tional treatment effect over time. The “pessimistic”
assumption was that the curves gradually came
back together after the trial suggesting a rebound
effect in the death rate after the trial (i.e., the zido-
vudine patients died at a faster rate during the
extrapolation period). The third scenario effectively
lay between the other two and assumed that the,
after the trial follow-up, patients died at the same
rate after trial follow-up. The authors showed that,
depending on which assumption was considered the
most realistic, the cost per life-year gained for zido-
vudine varied markedly. This particular study was
deterministic but, in a probabilistic framework, a
possible extension would have been to model a fam-
ily of possible survival curves reﬂecting different
extrapolation assumptions. Appropriately parame-
terized, it would have been possible to assess the
EVPI regarding additional research on long-term
survival.
Uncertainty about future treatment effects has
also been a feature of the cost-effectiveness litera-
ture on cholesterol-lowering therapies. In the eco-
nomic evaluation of the WOSCOPS study, the trial
provided estimates of reductions in mortality over
a period of 5 years. Nevertheless, to establish the
increase in mean survival duration associated with
the use of pravastatin, an estimate of the life expect-
ancy of patients who had survived that period was
necessary. The authors assumed that, after the 5-
year period, patients would cease taking the therapy
and those in both arms of the trial would die at the
same rate as the general population [43].
One element of the uncertainty associated with
the intermediate-to-ﬁnal outcome relationship, is
whether the nature of the relationship is stable
across different therapies or varies depending on
what intervention is used to affect the intermediate
measure. These features of the model can be dealt
with by adding further uncertainty to the parameter
distributions. This allows the measure of decision
uncertainty to include all relevant uncertainty
associated with cost-effectiveness. All things being
equal, the more uncertain the intermediate-to-ﬁnal
outcome relationship or the nature of the treatment
effect in the future, the greater the decision uncer-
tainty associated with reimbursing a given therapy.
The overall EVPI associated with a decision about
a therapy will also reﬂect uncertainty about these
parameters. Furthermore, an EVPI associated with
the speciﬁc parameter(s) which deﬁne the interme-
diate-outcome relationship or the nature of treat-
ment effects beyond the trial can be calculated. This
will indicate whether additional research is poten-
tially efﬁcient to estimate these parameters.
Policy Implications of the Framework
In making decisions about whether or not to reim-
burse new pharmaceuticals, health-care systems will
frequently face the question of when they have
enough information to justify reimbursement. This
question can only be addressed when there is a clear
and explicit objective from delivering health care—
that is, the objective function is deﬁned—and an
explicit budget constraint is indicated. The assumed
objective  function  in  the  case  study  in  this  article
is health gain measured in terms of QALYs; the
assumed budget constraint relates to the perspective
of the health-care system. The value of the frame-
work is not, however, tied to these perspectives. The
insistence on being 95% sure that the new product
is more cost-effective than its appropriate compara-
tor(s)—which would be implied if the standard
rules of statistical inference were adhered to—will
be inconsistent with any objective function.
If the appropriate focus is on expected cost-
effectiveness, why is it necessary to place so much
emphasis of quantifying the uncertainty? The
answer to this is that the decision uncertainty faced
by the decision maker is a key element in determin-
ing whether additional research should be under-
taken and, if so, the nature of that additional
research. The appropriate design of additional
research, including the optimal sample size, is deter-
mined by the balance between the marginal cost and
marginal beneﬁt, in terms of reducing the cost of
uncertainty, of collecting additional data [30]. A
decision about whether or not to reimburse a new
intervention based on existing evidence will there-
fore only be an interim one if it is still efﬁcient to
undertake additional research—that is, if the value
of perfect information is greater than the cost of col-
lecting additional data. Therefore, the answer to the
question “when is there sufﬁcient evidence to reim-
burse a new product?” is “when it is inefﬁcient to
collect additional data.”
This framework for reimbursement decision
making has some profound implications. The ﬁrst is
that the decision about whether to reimburse, based
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on existing data, needs to be taken simultaneously
with the decision regarding whether additional
research is to be undertaken. Currently, most reim-
bursement agencies internationally focus largely on
the ﬁrst of these decisions. NICE is unusual in that
it has the responsibility to recommend topics for
additional research. Nevertheless, it has limited
authority to ensure that this research is undertaken
to particular timelines. “Joining up” decisions
about reimbursement and additional research will
therefore be an important feature of any rational
system for reimbursement decisions.
A second implication is that there will be no
“standard” type or amount of evidence which will
be required for every new product for each patient
group. Rather, the amount and type of evidence will
depend on the value of additional research generally
and, in particular, that relating to individual param-
eters. The type and extent of evidence will therefore
be an empirical question, itself informed by analy-
sis. This contrasts with the existing formulaic
approach to what constitutes adequate evidence.
For a given intervention, the decision theoretic
framework may, then, lead to greater or lesser
research demands than the existing framework.
A third implication is that the framework will
rest on the adequacy of the model and, in particular,
on how fully all forms of uncertainty have been
characterized. This is particularly important given
the fact that, for most reimbursement authorities
internationally, the models are submitted by the
manufacturers who will have an incentive to under-
estimate the uncertainty associated with the cost-
effectiveness of their products. It is essential that the
decision makers are informed by adequate critical
review and interrogation of the manufacturers’
analyses and, if necessary, that these are augmented
or replaced by independent analyses. This mirrors
closely the existing arrangements for modeling to
inform the NICE technology appraisal process [47].
Ultimately, it is important that all features of a
model are explicit and open to challenge, with the
opportunity to assess the implications for cost-
effectiveness and value of information of alternative
formulations.
A fourth implication relates to whether a new
product should be reimbursed while additional evi-
dence is gathered. The framework suggests that if
the intervention’s expected costs and effects, relative
to appropriate comparators, suggest it is cost-
effective based on existing evidence (e.g., its ICER is
less than the opportunity cost of implementing it),
then it should be reimbursed, even if it is efﬁcient to
require additional evidence. Nevertheless, this raises
some important issues such as whether the reim-
bursement agencies have the powers to reverse a
decision if the additional research subsequently sug-
gests that the product is not cost-effective. Although
there are ways of reﬂecting the “costs” of the pos-
sible need to reverse a decision in the analysis
informing the adoption and future research deci-
sions [48], it may be considered too difﬁcult to
reimburse a new product, require additional evi-
dence and then risk having to withdraw funding.
The alternative would be to delay reimbursement
until an efﬁcient level of research has been under-
taken. Nevertheless, it is important to recognize
that such a delay will have opportunity costs in
terms of health beneﬁts which are not conferred on
patients and/or additional resource costs. This “cost
of delay” can be formally quantiﬁed using the deci-
sion theoretical framework, and this can provide a
further source of information to decision-makers
[10].
If adopted, this framework will face pharmaceu-
tical manufacturers with a range of new incentives.
Some of these are desirable. For example, compa-
nies are more likely to gather evidence, during the
drug development process, which directly informs
cost-effectiveness, and to ensure that this is sufﬁ-
cient at the point at which they apply for reimburse-
ment. Indeed, there is an important role for decision
theory and value of information analysis to inform
intracompany decisions about drug development
[49]. Nevertheless, there are some potentially nega-
tive incentives which would need to be addressed.
Perhaps most importantly, companies who are sec-
ond- (or subsequent) to-market within a new class
of drug are likely to free-ride on the research under-
taken by the company which was ﬁrst-to-market
[50]. For example, this may relate to research
undertaken by those ﬁrst-to-market to establish the
link between an intermediate measure of effect and
ultimate health gain which could be used by com-
panies which are later to market because it would
be largely common to all products in that class. If
not addressed, free-riding of this type could lead to
market failure and inefﬁcient levels of drug devel-
opment. To address this issue, which is a classic
public good problem, policy makers may have to
create an environment whereby the company which
is ﬁrst-to-market is guaranteed some property rights
over the research they undertake.
Conclusions
Reimbursement decision-making needs to be sup-
ported by an analytical framework which is explicit
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about all forms of uncertainty relating to a prod-
uct’s cost-effectiveness, which is able to establish
whether the intervention is expected to be cost-
effective based on existing evidence, and whether
additional research to reduce uncertainty when this
adoption decision is revisited is itself efﬁcient. An
implication of such a framework is that, only when
the costs of undertaking additional research are
greater than its beneﬁts in terms of reducing uncer-
tainty, is there sufﬁcient evidence regarding the cost-
effectiveness of an intervention.
Some may consider the decision theoretical
framework too speculative. It is certainly true that,
when attempting to characterize the uncertainties in
a decision problem when there is a lack, or absence,
of evidence, speculation and judgment is inevitable.
In such a situation, the available options would be,
ﬁrst, to ignore those elements of a model for which
evidence of an “acceptable quality” is unavailable,
in which case the analysis will be partial and biased.
The second option would be only to appraise tech-
nologies where complete and good quality evidence
has already been produced, in which case research
will focus on relatively simple questions where solu-
tions already exist. The third, and only rational,
option is to address complex and uncertain prob-
lems in an explicit way, based on evidence when
available, but to accept speculation and judgment
when it is not, and to require additional research
when that would represent an efﬁcient use of
resources.
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